130 related articles for article (PubMed ID: 10962312)
21. [Delayed therapy of clinically localized prostatic carcinoma. Experiences of the Karolinska Hospital].
Adolfsson J
Urologe A; 1996 Nov; 35(6):454-5. PubMed ID: 9064882
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
23. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
24. [Non-curative treatment of prostate carcinoma. Outcome in Göteborg].
Aus G; Hugosson J
Urologe A; 1996 Nov; 35(6):449-53. PubMed ID: 9064881
[TBL] [Abstract][Full Text] [Related]
25. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
26. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
Hattangadi JA; Chen MH; D'Amico AV
BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.
Stattin P; Bergh A; Karlberg L; Tavelin B; Damber JE
Eur Urol; 1997; 32(4):404-9. PubMed ID: 9412796
[TBL] [Abstract][Full Text] [Related]
28. Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study.
Wilson KM; Bälter K; Möller E; Adami HO; Andrén O; Andersson SO; Grönberg H; Mucci LA
Cancer Causes Control; 2013 Aug; 24(8):1575-81. PubMed ID: 23702886
[TBL] [Abstract][Full Text] [Related]
29. [Mortality due to prostatic carcinoma in northern Sweden].
Damber JE; Grönberg H
Urologe A; 1996 Nov; 35(6):443-5. PubMed ID: 9064879
[TBL] [Abstract][Full Text] [Related]
30. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer.
Daskivich TJ; Fan KH; Koyama T; Albertsen PC; Goodman M; Hamilton AS; Hoffman RM; Stanford JL; Stroup AM; Litwin MS; Penson DF
Ann Intern Med; 2013 May; 158(10):709-17. PubMed ID: 23689764
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment results of elderly patients with prostate cancer in Japan: an analysis of prognostic factors.
Kanamaru H; Arai Y; Akino H; Suzuki Y; Oyama N; Yoshida H; Okada K
Jpn J Clin Oncol; 1999 Mar; 29(3):151-5. PubMed ID: 10225698
[TBL] [Abstract][Full Text] [Related]
32. A better prognosis for obese men with prostate cancer.
Daniell HW
J Urol; 1996 Jan; 155(1):220-5. PubMed ID: 7490839
[TBL] [Abstract][Full Text] [Related]
33. Reliability of death certificates in prostate cancer patients.
Fall K; Strömberg F; Rosell J; Andrèn O; Varenhorst E;
Scand J Urol Nephrol; 2008; 42(4):352-7. PubMed ID: 18609293
[TBL] [Abstract][Full Text] [Related]
34. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
35. Temporal changes in survival in men with
Westerberg M; Franck Lissbrant I; Damber JE; Robinson D; Garmo H; Stattin P
Acta Oncol; 2020 Jan; 59(1):106-111. PubMed ID: 31526166
[No Abstract] [Full Text] [Related]
36. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series.
Adolfsson J; Steineck G; Hedlund PO
Urology; 1997 Nov; 50(5):722-6. PubMed ID: 9372882
[TBL] [Abstract][Full Text] [Related]
37. Trends in survival of prostate cancer in southeastern Netherlands, 1971-1989.
Post PN; Kil PJ; Coebergh JW
Int J Cancer; 1999 May; 81(4):551-4. PubMed ID: 10225443
[TBL] [Abstract][Full Text] [Related]
38. [Natural disease course in untreated early prostatic carcinoma--the Orebro Study].
Johansson JE
Praxis (Bern 1994); 2001 Sep; 90(36):1507-14. PubMed ID: 11593906
[TBL] [Abstract][Full Text] [Related]
39. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
[TBL] [Abstract][Full Text] [Related]
40. The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate.
Sandblom G; Ladjevardi S; Garmo H; Varenhorst E
Cancer; 2008 Feb; 112(4):813-9. PubMed ID: 18098207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
